tiprankstipranks
Alphamab Oncology (HK:9966)
:9966
Hong Kong Market

Alphamab Oncology (9966) Stock Forecast & Price Target

2 Followers
See the Price Targets and Ratings of:

9966 Analyst Ratings

Moderate Buy
1Ratings
Moderate Buy
1 Buy
0 Hold
0 Sell
Based on 1 analysts giving stock ratings to
Alphamab
Oncology
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

9966 Stock 12 Month Forecast

Average Price Target

HK$9.60
▲(2.24% Upside)
Based on 1 Wall Street analysts offering 12 month price targets for Alphamab Oncology in the last 3 months. The average price target is HK$9.60 with a high forecast of HK$9.60 and a low forecast of HK$9.60. The average price target represents a 2.24% change from the last price of HK$9.39.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"HK$2","7":"HK$7","12":"HK$12","4.5":"HK$4.5","9.5":"HK$9.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":9.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$9.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$9.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$9.60</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,4.5,7,9.5,12],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2024","6":"Jun<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.05,8.16923076923077,8.288461538461538,8.407692307692308,8.526923076923078,8.646153846153847,8.765384615384615,8.884615384615385,9.003846153846155,9.123076923076923,9.242307692307692,9.361538461538462,9.48076923076923,{"y":9.6,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.05,8.16923076923077,8.288461538461538,8.407692307692308,8.526923076923078,8.646153846153847,8.765384615384615,8.884615384615385,9.003846153846155,9.123076923076923,9.242307692307692,9.361538461538462,9.48076923076923,{"y":9.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.05,8.16923076923077,8.288461538461538,8.407692307692308,8.526923076923078,8.646153846153847,8.765384615384615,8.884615384615385,9.003846153846155,9.123076923076923,9.242307692307692,9.361538461538462,9.48076923076923,{"y":9.6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.8,"date":1706745600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.8,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.8,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.8,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.8,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.8,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.15,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.14,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.5,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.45,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.8,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.73,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.05,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetHK$9.60Average Price TargetHK$9.60Lowest Price TargetHK$9.60
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Jefferies Analyst forecast on HK:9966
Jefferies
Jefferies
HK$9.6
Buy
2.24%
Upside
Reiterated
03/27/26
Alphamab Oncology (9966) Gets a Buy from Jefferies
Sinolink Securities Analyst forecast on HK:9966
Unknown Analyst
Sinolink Securities
Not Ranked
Sinolink Securities
HK$14.3
Buy
52.29%
Upside
Reiterated
12/20/25
Alphamab Oncology (9966) Receives a Buy from Sinolink Securities
BOCOM International Holdings Company Analyst forecast on HK:9966
Unknown Analyst
BOCOM International Holdings Company
Not Ranked
BOCOM International Holdings Company
HK$13
Buy
38.45%
Upside
Reiterated
12/13/25
Alphamab Oncology (9966) Receives a Buy from BOCOM International Holdings Company
GF Securities Analyst forecast on HK:9966
Unknown Analyst
GF Securities
Not Ranked
GF Securities
HK$12.89
Buy
37.27%
Upside
Reiterated
06/12/25
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Jefferies Analyst forecast on HK:9966
Jefferies
Jefferies
HK$9.6
Buy
2.24%
Upside
Reiterated
03/27/26
Alphamab Oncology (9966) Gets a Buy from Jefferies
Sinolink Securities Analyst forecast on HK:9966
Unknown Analyst
Sinolink Securities
Not Ranked
Sinolink Securities
HK$14.3
Buy
52.29%
Upside
Reiterated
12/20/25
Alphamab Oncology (9966) Receives a Buy from Sinolink Securities
BOCOM International Holdings Company Analyst forecast on HK:9966
Unknown Analyst
BOCOM International Holdings Company
Not Ranked
BOCOM International Holdings Company
HK$13
Buy
38.45%
Upside
Reiterated
12/13/25
Alphamab Oncology (9966) Receives a Buy from BOCOM International Holdings Company
GF Securities Analyst forecast on HK:9966
Unknown Analyst
GF Securities
Not Ranked
GF Securities
HK$12.89
Buy
37.27%
Upside
Reiterated
06/12/25
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Alphamab Oncology

3 Months
xxx
Success Rate
1/1 ratings generated profit
100%
Average Return
+53.90%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +53.90% per trade.
1 Year
Cui CuiJefferies
Success Rate
1/1 ratings generated profit
100%
Average Return
+21.90%
reiterated a buy rating 18 days ago
Copying Cui Cui's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +21.90% per trade.
2 Years
xxx
Success Rate
1/1 ratings generated profit
100%
Average Return
+21.90%
reiterated a xxx
rating 18 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +21.90% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

9966 Analyst Recommendation Trends

Rating
Nov 25
Dec 25
Jan 26
Feb 26
Mar 26
Strong Buy
1
0
0
0
0
Buy
6
7
9
9
9
Hold
11
10
15
16
16
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
18
17
24
25
25
In the current month, 9966 has received 9 Buy Ratings, 16 Hold Ratings, and 0 Sell Ratings. 9966 average Analyst price target in the past 3 months is 9.60.
Each month's total comprises the sum of three months' worth of ratings.

9966 Financial Forecast

9966 Earnings Forecast

The previous quarter’s earnings for 9966 were -HK$0.15.
The previous quarter’s earnings for 9966 were -HK$0.15.

9966 Sales Forecast

The previous quarter’s earnings for 9966 were HK$270.18M.
The previous quarter’s earnings for 9966 were HK$270.18M.

9966 Stock Forecast FAQ

What is HK:9966’s average 12-month price target, according to analysts?
Based on analyst ratings, Alphamab Oncology’s 12-month average price target is 9.60.
    What is HK:9966’s upside potential, based on the analysts’ average price target?
    Alphamab Oncology has 2.24% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Alphamab Oncology a Buy, Sell or Hold?
          Alphamab Oncology has a consensus rating of Moderate Buy, which is based on 1 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Alphamab Oncology’s share price target?
            The average share price target for Alphamab Oncology is 9.60. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is HK$9.60 ,and the lowest forecast is HK$9.60. The average share price target represents 2.24% Increase from the current price of HK$9.39.
              What do analysts say about Alphamab Oncology?
              Alphamab Oncology’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
                How can I buy shares of Alphamab Oncology?
                To buy shares of HK:9966, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.